Expanding anti-CD38 immunotherapy for lymphoid malignancies
暂无分享,去创建一个
M. Zhang | K. Young | Ming Liu | Yong Li | Ling Li | Xinfang Yu | Wei Li | X. Fang | P. Neeli | Xu Wang
[1] M. Kersten,et al. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma , 2021, Blood advances.
[2] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[3] Xu Wang,et al. MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis. , 2020, Blood.
[4] Xu Wang,et al. Targeting PD-L1 in non-small cell lung cancer using CAR T cells , 2020, Oncogenesis.
[5] A. Yen,et al. Roscovitine enhances all-trans retinoic acid (ATRA)-induced nuclear enrichment of an ensemble of activated signaling molecules and augments ATRA-induced myeloid cell differentiation , 2020, Oncotarget.
[6] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[7] Michael L. Wang,et al. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. , 2019, Clinical lymphoma, myeloma & leukemia.
[8] F. Malavasi,et al. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma , 2018, Front. Immunol..
[9] S. Usmani,et al. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance , 2018, Front. Immunol..
[10] G. Ossenkoppele,et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia , 2018, Haematologica.
[11] E. Dmitrovsky,et al. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. , 2018, Cancer discovery.
[12] M. Loh,et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. , 2018, Blood.
[13] P. Richardson,et al. CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.
[14] K. Goldberg,et al. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy , 2017, The oncologist.
[15] Huipin Yuan,et al. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] P. Hari,et al. Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. , 2016, The New England journal of medicine.
[17] T. Luetkens,et al. Immunotherapies targeting CD38 in Multiple Myeloma , 2016, Oncoimmunology.
[18] Renier J. Brentjens,et al. Driving CAR T-cells forward , 2016, Nature Reviews Clinical Oncology.
[19] P. Parren,et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma , 2015, Haematologica.
[20] R. Groen,et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab , 2015, Leukemia.
[21] Yu-jing Zhang,et al. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type , 2015, Annals of Hematology.
[22] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[23] J. Laubach,et al. Daratumumab granted breakthrough drug status , 2014, Expert opinion on investigational drugs.
[24] O. Shpilberg,et al. Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling. , 2013, Leukemia research.
[25] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[26] R. Morgan,et al. Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry , 2012, Journal of Translational Medicine.
[27] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[28] Jeffrey D Varner,et al. Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-monoblastic leukemia cells , 2011, Leukemia & lymphoma.
[29] H. Nakamine,et al. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab , 2009, International journal of hematology.
[30] W. Wilson,et al. Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor , 2008 .
[31] M. Lichtman. Battling the hematological malignancies: the 200 years' war. , 2008, The oncologist.
[32] D. Catovsky,et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH , 2007, British journal of haematology.
[33] L. Medeiros,et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. , 2005, American journal of clinical pathology.
[34] D. Rawlings,et al. CD38 Signaling Regulates B Lymphocyte Activation via a Phospholipase C (PLC)-γ2-Independent, Protein Kinase C, Phosphatidylcholine-PLC, and Phospholipase D-Dependent Signaling Cascade1 , 2005, The Journal of Immunology.
[35] Yuan-fang Liu,et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] K. Kawa,et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells , 2004, Leukemia.
[37] G. Tricot,et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. , 2004, American journal of clinical pathology.
[38] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[39] V. Diehl,et al. Challenges in treating hematologic malignancies. , 2002, Seminars in oncology.
[40] C. Bloomfield,et al. All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .
[41] G Shubinsky,et al. The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. , 1997, Immunity.